Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Codexis, Inc.
Codexis sells engineered enzymes and technology to pharmaceutical companies to help them manufacture medicines more efficiently.
Codexis makes the molecular machines that drugmakers use to build medicines. Its core product is engineered enzymes — proteins that act as tiny chemical factories, speeding up reactions that would otherwise be slow, messy, or expensive. Pharmaceutical companies buy these enzymes, and the custom processes that come with them, to manufacture drugs more cheaply and with less waste.
The business sits at the tricky frontier of making complex medicines. Many modern drugs, especially the newer classes of treatments, are hard to synthesize at commercial scale. Codexis engineers enzymes through a process called directed evolution — essentially breeding proteins in the lab, generation after generation, until they perform a desired chemical reaction well. Customers pay for the enzyme and the know-how to slot it into their manufacturing lines. The pitch is straightforward: a better enzyme means fewer chemical steps, lower cost, and less toxic waste. Codexis is a small company in a world of giant customers, which cuts both ways. Winning a spot in a drugmaker's manufacturing process can lock in recurring enzyme orders for years, because once a production line is built around a specific enzyme, switching is painful. But the company depends on a handful of large partners and on the drug industry's spending cycles. It has also pushed into areas beyond classic small-molecule drugs, including enzymes for making nucleic-acid-based medicines, an emerging field that could broaden its customer base if it pays off.
The company is based in Redwood City, California, and it is not yet consistently profitable — it spends heavily on research to keep its enzyme library ahead of competitors, and its results swing with the timing of customer projects and milestone payments. Investors are essentially betting that as medicine becomes more biologically engineered, more drugmakers will pay for Codexis's custom-built proteins to do the chemistry for them.
Saved answer · last researched 15 Nov 2026